Chemed Corporation: UBS initiates coverage with buy rating and $650 target price
CHE•UBS initiated coverage of Chemed Corporation with a buy rating and a $650 target price.
Related News
Pharming announces FDA acceptance of sNDA for lower Joenja doses
PHAR•
Wall St edges up as AI enthusiasm eases worries over higher oil prices, yields
SPY•
BP explored deal for Devon’s Eagle Ford asset, sources say
BP•
Nasdaq trade halt continues; reason unavailable at 10:06 a.m.
UCFI•
Nasdaq trading halt continues; reason unavailable at 10:11 a.m.
UCFI•